Related Experiment Video
Updated: Mar 29, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Can artificial intelligence bridge the gaps for primary diabetes care in low-income and middle-income countries?
Zhouyu Guan1, Huating Li1, Sergio Hernández-Jiménez2
1Shanghai Belt and Road International Joint Laboratory for Intelligent Prevention and Treatment of Metabolic Disorders, School of Computer Science, Shanghai Jiao Tong University, Institute for Proactive Healthcare, Shanghai Jiao Tong University, Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Diabetes Institute, Shanghai Clinical Centre for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Shanghai Jiao Tong University, Shanghai, China.
Abstract:
Artificial intelligence (AI) has the potential to improve primary diabetes care in low-income and middle-income countries (LMICs), where the rising burden of disease contrasts sharply with limited health-care resources. Emerging evidence shows the promise of AI for screening, risk prediction, monitoring, and personalised management of diabetes and its complications. However, substantial barriers remain, including infrastructure deficits, data fragmentation, equity and inclusivity challenges, limited prospective validation, and concerns about the acceptability, sustainability, and regulatory oversight of AI. The effective integration of AI into primary diabetes care will depend on coordinated investment in foundational infrastructure that includes large-scale development and rigorous validation of novel AI models for use by primary care physicians and patients across diverse populations. AI initiatives are also needed to support interdisciplinary and international collaborations spanning clinical, technical, and policy domains to ensure successful implementation. By aligning technological innovation with health care needs, AI could evolve from a proof-of-concept tool to a practical enabler of equitable, scalable, and cost-effective diabetes care in LMICs. In this Personal View, we outline the major opportunities and challenges of applying AI to primary diabetes care in LMICs, and propose directions for future development and implementation.
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Symptoms, Diagnosis, and Complications

